KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) Equity Average (2016 - 2025)

Historic Equity Average for Charles River Laboratories International (CRL) over the last 16 years, with Q3 2025 value amounting to $3.4 billion.

  • Charles River Laboratories International's Equity Average fell 990.39% to $3.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 billion, marking a year-over-year decrease of 990.39%. This contributed to the annual value of $3.5 billion for FY2024, which is 738.03% up from last year.
  • As of Q3 2025, Charles River Laboratories International's Equity Average stood at $3.4 billion, which was down 990.39% from $3.3 billion recorded in Q2 2025.
  • Charles River Laboratories International's Equity Average's 5-year high stood at $3.8 billion during Q3 2024, with a 5-year trough of $2.2 billion in Q1 2021.
  • Over the past 5 years, Charles River Laboratories International's median Equity Average value was $3.2 billion (recorded in 2023), while the average stood at $3.0 billion.
  • As far as peak fluctuations go, Charles River Laboratories International's Equity Average surged by 3220.98% in 2021, and later plummeted by 1103.22% in 2025.
  • Quarter analysis of 5 years shows Charles River Laboratories International's Equity Average stood at $2.5 billion in 2021, then increased by 12.93% to $2.8 billion in 2022, then increased by 23.14% to $3.5 billion in 2023, then grew by 4.93% to $3.6 billion in 2024, then fell by 6.67% to $3.4 billion in 2025.
  • Its Equity Average stands at $3.4 billion for Q3 2025, versus $3.3 billion for Q2 2025 and $3.3 billion for Q1 2025.